Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
19/05/2026 14:59
May 19 (Reuters) - Orexo AB ORX.ST: OREXO ANNOUNCES POSITIVE OUTCOME FROM AN IN-VIVO STUDY OF OX390 OREXO AB - STUDY ESTABLISHES PROOF-OF-CONCEPT FOR INTRANASAL ATIPAMEZOLE DELIVERY OREXO AB - SINGLE NASAL DOSE OF OX390 ACHIEVES TARGETED THERAPEUTIC EXPOSURE Source text: ID:nPn85L7tba Further company coverage: ORX.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens